Table 4

Rb immunohistochemistry before and after E7070

PatientAntibody% (2+, 3+) pretreatment% (2+, 3+) posttreatmentClinical outcome
1aAnti-Rbb (pT821)325PD after two cycles
Anti-Rb (pS795)8621
Anti-Rb (total)7980
2cAnti-Rb (pT821)130SD after two cycles; PD after four cycles
Anti-Rb (pS795)410
3dAnti-Rb (pT821)400SD after four cycles; PD after five cycles
Anti-Rb (pS795)805
Anti-Rb (pS807/811)800
Anti-Rb (total)7050
  • a Patient 1: Ki67, pretreatment 10%; posttreatment 3%.

  • b Rb, retinoblastoma; PD, progressive disease; SD, disease.

  • c Patient 2: Ki67, pretreatment 1%; posttreatment 3%.

  • d Patient 3: PCNA, pretreatment 30%; posttreatment 20%.